C71T
CANCELLED SECTION 71
06/02/2026
Voltar para busca
Dado oficial do USPTO
NMD NEUROMUSCULAR DISORDERS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
03/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
18/05/2018
Data de registro
23/07/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/02/2026
Última transação
03/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
DK
Examinador
KIDWELL WALKER, JACLYN NOEMI
Unidade examinadora
L20
Localização atual
TMEG LAW OFFICE 102
Descrição da marca
The mark consists of the letters "NMD" in dark grey with a green diamond over the letter "M" followed by the wording "NEUROMUSCULAR DISORDERS" in light grey with "NEUROMUSCULAR" above the word "DISORDERS" and with a vertical grey line between "NMD" and "NEUROMUSCULAR DISORDERS".
Titulares e representantes
Titulares
NMD Pharma A/S
Representantes
Joel D. Leviton STINSON LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemical-pharmaceutical preparations for the treatment of rare and genetic diseases; chemical-pharmaceutical preparations for the treatment of neurodegenerative diseases; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders; chemical-pharmaceutical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; chemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by compromised skeletal muscle excitability; diagnostic preparations for medical purposes; reagents for medical purposes and for research ; preparations for analysis for medical and research purposes; pharmaceutical and medical preparations for the treatment of rare and genetic diseases; pharmaceutical and medical preparations for the treatment of neurodegenerative diseases; pharmaceutical and medical preparations for the treatment of neuromuscular disorders; pharmaceutical and medical preparations that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; pharmaceutical and medical preparations for acute hospital carechemical-pharmaceutical preparations for the reversal of neuromuscular blockadechemical-pharmaceutical preparations for the treatment of intensive care unit acquired muscle weaknesschemical-pharmaceutical preparations for the treatment of neuromuscular disorders caused by infections
Classe 42
Scientific and technological services and researchresearch in the field of medicine and the development of pharmaceutical preparations; industrial analysis and research services in the field of development of pharmaceutical preparationsin the field of identification of drug candidates; drug discovery services; basic research and clinical researchhereunder in the field of medicine and vaccine development; development of medical treatments related to rare and genetic diseases; development of medical treatments related to neurodegenerative diseases; development of medical treatments related to neuromuscular disorders; development of medical treatments that strengthen neuromuscular transmission and muscle function in patients with neuromuscular disorders; development of medical treatments for acute hospital care
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
23/07/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/09/2023
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
29/08/2020
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
26/07/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/12/2019
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
21/11/2019
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/11/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/11/2019
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
14/11/2019
FIMP
FINAL DISPOSITION PROCESSED
14/11/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/10/2019
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
23/08/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
23/07/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/05/2019
PUBO
PUBLISHED FOR OPPOSITION
07/05/2019
GPNX
NOTIFICATION PROCESSED BY IB
03/05/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/04/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/04/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/04/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/04/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/03/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
18/03/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
18/03/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
18/03/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/03/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/03/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/03/2019
RFNT
REFUSAL PROCESSED BY IB
13/10/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/09/2018
RFRR
REFUSAL PROCESSED BY MPU
21/09/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
18/09/2018
CNRT
NON-FINAL ACTION WRITTEN
17/09/2018
DOCK
ASSIGNED TO EXAMINER
10/09/2018
MAFR
APPLICATION FILING RECEIPT MAILED
24/08/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/08/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/08/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NMD NEUROMUSCULAR DISORDERS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.